Stocklytics Platform
Asset logo for symbol MRSN
Mersana Therapeutics
MRSN63
$1.35arrow_drop_down4.92%-$0.07
Penny Stock
Asset logo for symbol MRSN
MRSN63

$1.35

arrow_drop_down4.92%
Key Stats
Open$1.41
Prev. Close$1.42
EPS-0.85
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$165.61M
PE Ratio-
LOWHIGH
Day Range1.28
1.43
52 Week Range1.06
6.28
Ratios
EPS-0.85
Fundamentals
Payout Ratio-
Industry average yield2.95%
Last Dividend pay date-
Dividend per share-
Dividend yield forecast-

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Stock Performance

MRSNarrow_drop_down4.93%
US Healthcare Sectorarrow_drop_down0.54%
US Marketarrow_drop_down1.01%
warning

MRSN / Market

MRSN lose to the US Market which returned -1.01% over the last twenty four hours.
warning

MRSN / Healthcare Sector

MRSN lose to the US Healthcare sector which returned -0.54% over the last twenty four hours.

Mersana Therapeutics (MRSN) Statistics

Mersana Therapeutics Inc (MRSN) is a biopharmaceutical company that develops innovative antibody drug conjugates (ADCs) for the treatment of cancer. The company is focused on utilizing its proprietary Fleximer platform to create next-generation ADCs that offer enhanced efficacy and safety compared to traditional chemotherapy. Mersana's lead product candidate, XMT-1536, is currently in clinical development for the treatment of patients with ovarian cancer and non-small cell lung cancer. The company is also advancing a robust pipeline of ADC candidates targeting multiple tumor types.
In terms of valuation metrics, Mersana Therapeutics Inc has a market capitalization of $XXX.XX million and an enterprise value of $XXX.XX million. The stock has a price-to-sales ratio of X.XX, indicating a relatively high valuation compared to its revenue. The company's enterprise to EBITDA ratio, a measure of its operating performance, is X.XX, which suggests that it may be overvalued relative to its earnings. Mersana Therapeutics Inc's profit margin is not available at this time, as the company is still in the early stages of commercialization.
add Mersana Therapeutics  to watchlist

Keep an eye on Mersana Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

How has Mersana Therapeutics (MRSN) stock's performance compared to its sector and the market over the past year?

Over the past year, Mersana Therapeutics (MRSN) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 25.67%, Mersana Therapeutics has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 60.84%, it has fallen short of the market average. This comparison highlights Mersana Therapeutics 's performance relative to both its sector and the overall market over the last year.
help

What is the PE ratio of Mersana Therapeutics (MRSN) stock?

The PE ratio for Mersana Therapeutics (MRSN) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.
help

What is the EPS of Mersana Therapeutics (MRSN) stock?

The Earnings Per Share (EPS) for Mersana Therapeutics (MRSN), calculated on a diluted basis, is -$0.85. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.
help

What is the operating margin of Mersana Therapeutics (MRSN) stock?

The operating margin for Mersana Therapeutics (MRSN) is -1.11K%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.
help

What is the EBITDA of Mersana Therapeutics (MRSN) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Mersana Therapeutics (MRSN) is -$101.41M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.
help

How much debt does Mersana Therapeutics (MRSN) have?

Mersana Therapeutics (MRSN) has a total debt of $32.93M. The net debt, which accounts for cash and cash equivalents against the total debt, is -$26.69M.

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level

Stocklytics Platform

© 2024 Stocklytics.com All rights reserved.

Stocklytics.com is not a financial advisor, and all data and information provided on this website are for informational purposes only. The content on Stocklytics.com is not intended to be a substitute for professional financial advice. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions. Stocklytics.com makes no representations or warranties regarding the accuracy, completeness, or suitability of any information provided and is not liable for any errors or omissions, or for any losses incurred as a result of reliance on the information provided on this website.

Stocklytics Discord public channelStocklytics X Social Media